APONTIS PHARMA Reports Strong Q1 2025 Performance

APONTIS PHARMA AG, a leader in Single Pill combinations, announced a strong start to 2025 with group sales increasing to EUR 12.9 million, up from EUR 10.0 million in Q1 2024. This growth was driven by a EUR 0.6 million rise in Single Pill combination revenue, offsetting a EUR 1.0 million decline at Tonotec. EBITDA improved to EUR 1.3 million, reflecting higher revenues and reduced costs. Net income saw a significant 93% jump to EUR 0.7 million.

Cooperation with Novartis boosted partnership business to EUR 3.3 million, over triple last year’s figure. APONTIS plans to expand its Single Pill offerings further in 2025, despite anticipated competition. The company remains confident in achieving a projected 16% sales increase to EUR 56.4 million by year-end.